NiCOX WEB NEWS: FEATURED ARTICLE
Nicox: Presentation of latanoprostene bunod data at ARVO 2014 Annual Meeting
...................................
May 12, 2014.
Latanoprostene bunod results were presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which took place from May 4 to May 8 in Orlando, Florida.
Results from two clinical studies (CONSTELLATION and KRONUS) were presented, as well as preclinical mechanism of action data.
For more information, please click here to read the full article on our website http://www.nicox.com/index.php/en/news-media/news/news-detail/presentations-at-arvo-2014-annual-meeting
...................................
This featured article may contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2012 » filed with the French Autorité des Marchés Financiers (AMF) on April 2, 2014 and available on Nicox's website (www.nicox.com) and on the AMF's website www.amf-france.org).
...................................
Nicox Contacts
Corporate Communications
Tel +33 (0)4 97 24 53 00 | communications@nicox.com